AI stock analysis · Electrical Equipment & Parts · Last analyzed Aug 20, 2026
Compass Score
3.0/5
Call
Hold
Price
$3.40
AI Target
$10.86 +219.5%
AI Analyst Summary
Enovix is a next-generation silicon-anode battery company whose bull thesis rests on its proprietary cell architecture winning design contracts in smartphones and wearables, with 20.8% YoY revenue growth validating early commercial traction. The analyst community is firmly constructive — 8 of 11 analysts rate the stock Buy with a mean price target of $10.86, implying over 3x upside from current levels — and management has beaten EPS estimates in each of the last four quarters, signaling disciplined execution. The central risk is that the company remains deeply loss-making, and any delay in scaling manufacturing or securing volume customer commitments could pressure the stock significantly given its speculative valuation.
Catalysts
Volume production ramp at Enovix's Agrate (Malaysia) Fab-2 facility, where yield improvements and cost-per-cell progress could trigger a meaningful upward EPS estimate revision cycle.
Announcement of a Tier-1 smartphone or wearable OEM design win, which would serve as a major commercial validation and likely re-rate the stock toward analyst price targets.
Q3/Q4 earnings releases where continued revenue acceleration beyond 20.8% YoY growth and narrowing operating losses could signal an approaching path to breakeven and attract growth-oriented institutional buyers.
Fundamentals
PeN/A (loss-making) · 1.0/5
No trailing P/E available; company is currently unprofitable with a negative forward P/E of -5.4x, indicating meaningful losses ahead. No clear near-term path to profitability based on available data.
PegN/A · 3.0/5
PEG ratio is unavailable due to negative earnings. Scored neutrally per guidelines, though the absence of profitability is a structural concern. Revenue growth of 20.8% YoY provides partial support.
Analyst RatingBuy consensus (1.8) · 4.0/5
Consensus of 1.8 from 11 analysts (8 Buy / 3 Hold / 1 Sell) maps to a score of 4. Broad analyst coverage with a strong skew toward Buy ratings reflects meaningful institutional conviction in the turnaround story.
EPS growth is not calculable given ongoing losses. Revenue growth of 20.8% YoY is encouraging and directionally positive, but the company has yet to translate top-line momentum into profitability, limiting this score.
Price Target Beat4 of 4 quarters beat · 5.0/5
Enovix has beaten EPS estimates in all 4 of the last 4 reported quarters. While the full 8-quarter history is unavailable, a perfect recent beat rate is a strong signal of consistent execution and management discipline.
ManagementConsistent EPS beater with strong analyst backing · 4.0/5
Perfect 4-of-4 EPS beat rate combined with strong analyst conviction (8 of 11 rated Buy) suggests management is effectively guiding expectations and executing on operational milestones. Capital allocation remains a watch item given continued losses.
● See the full picture
Get today's top-scored picks, ranked for you.
Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.
Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →
Not financial advice.
Compass is an analytical tool, not a registered investment adviser or broker-dealer.
Scores and recommendations are generated by AI, may be inaccurate or out of date, and are
not investment, financial, legal, or tax advice. Investing involves risk, including loss of
principal. Do your own research and consult a licensed financial professional.
About Compass.